Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Health systems and care delivery

Topic: Risk, prevention and care in population studies

Plain-language summary

Comorbidity indices for patients with cognitive impairment increased during the 6-year study period, especially after the index. Enrollment in Medicare Advantage Prescription Drug plans vs. commercial (OR = 1.60), dual Medicare/Medicaid eligibility (OR = 1.36), cerebrovascular disease (OR = 1.24), and PD medication use (OR = 1.46) were associated with a new cognitive impairment diagnosis (all p < 0.05). A greater proportion of patients with cognitive impairment had hospitalizations and emergency department visits and higher median total healthcare costs than controls for each year pre- and post-index. In patients with PD newly diagnosed with cognitive impairment, comorbidity burden, hospitalizations, emergency department visits, and total costs peaked 1-year pre- and post-identification. These data coupled with recommendations for annual screening for cognitive impairment in PD support the early diagnosis and management of cognitive impairment in order to optimize care for patients and their caregivers.

What this study adds

Evidence grade: Low

The record lists 2,711 participants. This study describes characteristics of patients with Parkinson's disease who were newly diagnosed with cognitive impairment, including more hospitalizations and higher healthcare costs. Reported effect size: OR = 1.60; OR = 1.36; OR = 1.24.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Chandler, J. M., Nair, R., Biglan, K., Ferries, E. A., Munsie, L. M., Changamire, T., et al. (2021). Characteristics of Parkinson’s Disease in Patients with and without Cognitive Impairment. Journal of Parkinson s Disease. https://doi.org/10.3233/jpd-202190

Vancouver

Chandler JM, Nair R, Biglan K, Ferries EA, Munsie LM, Changamire T, et al. Characteristics of Parkinson’s Disease in Patients with and without Cognitive Impairment. Journal of Parkinson s Disease. 2021. doi:10.3233/jpd-202190. PMID: 33720850.

BibTeX

@article{chandler2021-33720850,
  author  = {Chandler, Julie M. and Nair, Radhika and Biglan, Kevin and Ferries, Erin A. and Munsie, Leanne M. and Changamire, Tich and Patel, Nick C.},
  title   = {{Characteristics of Parkinson’s Disease in Patients with and without Cognitive Impairment}},
  journal = {Journal of Parkinson s Disease},
  year    = {2021},
  doi     = {10.3233/jpd-202190},
  pmid    = {33720850},
  url     = {https://doi.org/10.3233/jpd-202190}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This study describes characteristics of patients with Parkinson's disease who were newly diagnosed with cognitive impairment, including more hospitalizations and higher healthcare costs. It does not test any treatment, cure, or prevention for Alzheimer's disease, and it supports early diagnosis and management of cognitive impairment in Parkinson's disease.

Study details

How this study scored 49/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 3 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 49 of 100.49 of 100 points earned51 not earned

Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Parkinson s Disease)
Journal's citation record 1 / 4 Journal of Parkinson s Disease: journal h-index 97 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2021 — within 6 year(s) of the newest study here
Sample size 3 / 4 2,711 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 28 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.0 citations a year over 7 year(s) since 2021
Impact for its field and year 2 / 6 Cited 1.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 18 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Nick C. Patel: h-index 31 (OpenAlex, whole career)
Institution's track record 1 / 3 Eli Lilly (United States): institution h-index 744 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 33720850)
Free to read 2 / 2 Free to read
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Health systems and care delivery from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Health systems and care delivery

See all studies in Health systems and care delivery →